Related references
Note: Only part of the references are listed.Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation
Melanie R. Rutkowski et al.
CANCER CELL (2015)
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
Emily Chan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial
Renata Ursu et al.
CANCER SCIENCE (2015)
Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer
Tom J. H. Arends et al.
CLINICAL GENITOURINARY CANCER (2015)
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
Burghardt Wittig et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Autophagy in malignant transformation and cancer progression
Lorenzo Galluzzi et al.
EMBO JOURNAL (2015)
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
Martin R. Weihrauch et al.
EUROPEAN JOURNAL OF CANCER (2015)
MD-2 is required for disulfide HMGB1-dependent TLR4 signaling
Huan Yang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9
Umeharu Ohto et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs
Rachid Ammi et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation
Siqi Liu et al.
SCIENCE (2015)
Toll-like receptor 4 senses oxidative stress mediated by the oxidation of phospholipids in extracellular vesicles
Mateja Mancek-Keber et al.
SCIENCE SIGNALING (2015)
Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders
Stefano G. Daniele et al.
SCIENCE SIGNALING (2015)
PD-L1 Blockade for Cancer Treatment: MEDI4736
Ramy Ibrahim et al.
SEMINARS IN ONCOLOGY (2015)
Toll-like receptor 4 senses oxidative stress mediated by the oxidation of phospholipids in extracellular vesicles
Mateja Mancek-Keber et al.
SCIENCE SIGNALING (2015)
Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders
Stefano G. Daniele et al.
SCIENCE SIGNALING (2015)
Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer
Jitka Fucikova et al.
FRONTIERS IN IMMUNOLOGY (2015)
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
L. Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2015)
TLR7 induces anergy in human CD4+ T cells
Margarita Dominguez-Villar et al.
NATURE IMMUNOLOGY (2015)
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
David A. Smith et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9
Yuyi Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small Cell Lung Cancer
Saradiya Chatterjee et al.
CANCER RESEARCH (2014)
TLR Signals Induce Phagosomal MHC-I Delivery from the Endosomal Recycling Compartment to Allow Cross-Presentation
Priyanka Nair-Gupta et al.
CELL (2014)
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
Aaron P. Rapoport et al.
CLINICAL CANCER RESEARCH (2014)
The Histidine Transporter SLC15A4 Coordinates mTOR-Dependent Inflammatory Responses and Pathogenic Antibody Production
Toshihiko Kobayashi et al.
IMMUNITY (2014)
Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells
Yuliya Skabytska et al.
IMMUNITY (2014)
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-na⟨ve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
A. Ruzsa et al.
INVESTIGATIONAL NEW DRUGS (2014)
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
Hans-Joachim Schmoll et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
B lymphocytes undergo TLR2-dependent apoptosis upon Shigella infection
Katharina Nothelfer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness
Joseph M. Pickard et al.
NATURE (2014)
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
Tobias Bald et al.
NATURE (2014)
A cell-intrinsic role for TLR2 MYD88 in intestinal and breast epithelia and oncogenesis
Ferenc A. Scheeren et al.
NATURE CELL BIOLOGY (2014)
Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF
Joseph P. Kolb et al.
SCIENCE SIGNALING (2014)
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
Madhav V. Dhodapkar et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells
Juping Wang et al.
ONCOTARGET (2014)
Targeting Aerobic Glycolysis and HIF-1α Expression Enhance Imiquimod-induced Apoptosis in Cancer Cells
Shi-Wei Huang et al.
ONCOTARGET (2014)
Immunogenic cell death inducers as anticancer agents
Oliver Kepp et al.
ONCOTARGET (2014)
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice
Bojidar M. Kojouharov et al.
ONCOTARGET (2014)
Classification of current anticancer immunotherapies
Lorenzo Galluzzi et al.
ONCOTARGET (2014)
Could Hyaluronic acid (HA) reduce Bacillus Calmette-Guerin (BCG) local side effects? Results of a pilot study
Luca Topazio et al.
BMC UROLOGY (2014)
Novel immune checkpoint blocker approved for the treatment of advanced melanoma
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2014)
Combined OX40 ligation plus CTLA-4 blockade More than the sum of its parts
Stefanie N. Linch et al.
ONCOIMMUNOLOGY (2014)
Toll-like receptor agonists in oncological indications
Fernando Aranda et al.
ONCOIMMUNOLOGY (2014)
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
Linda C. Sandin et al.
ONCOIMMUNOLOGY (2014)
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
Lawrence J. Thomas et al.
ONCOIMMUNOLOGY (2014)
Trial watch: Dendritic cell-based anticancer therapy
Norma Bloy et al.
ONCOIMMUNOLOGY (2014)
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp et al.
ONCOIMMUNOLOGY (2014)
Trial Watch Chemotherapy with immunogenic cell death inducers
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
Trial Watch Tumor-targeting monoclonal antibodies in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
Assembly and localization of Toll-like receptor signalling complexes
Nicholas J. Gay et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant
Mark T. Orr et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
Jean-Pascal Machiels et al.
INVESTIGATIONAL NEW DRUGS (2013)
Decoding cell death signals in liver inflammation
Catherine Brenner et al.
JOURNAL OF HEPATOLOGY (2013)
Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer
Johannes Falke et al.
JOURNAL OF UROLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses
Christopher B. Fox et al.
VACCINE (2013)
Aldara activates TLR7-independent immune defence
Anne Walter et al.
NATURE COMMUNICATIONS (2013)
1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guerin immunotherapy of bladder cancer
Jong-Wei Hsu et al.
ONCOTARGET (2013)
Trial watch Monoclonal antibodies in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis
Su Yin Lim et al.
ONCOIMMUNOLOGY (2013)
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
Weiyi Peng et al.
ONCOIMMUNOLOGY (2013)
Inhibiting the inhibitors Checkpoints blockade in solid tumors
Domenico Mavilio et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Toll-like receptor agonists for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
Lana E. Kandalaft et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Peptide vaccines in cancer therapy
Fernando Aranda et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Dendritic cell-based interventions for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells
Shamaila Munir et al.
ONCOIMMUNOLOGY (2013)
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Hailing Lu et al.
CLINICAL CANCER RESEARCH (2012)
IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.
Marina Tschaika et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A TLR5 Agonist Enhances CD8+ T Cell-Mediated Graft-versus-Tumor Effect without Exacerbating Graft-versus-Host Disease
Xilai Ding et al.
JOURNAL OF IMMUNOLOGY (2012)
Inflammasomes in carcinogenesis and anticancer immune responses
Laurence Zitvogel et al.
NATURE IMMUNOLOGY (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Mitochondria: master regulators of danger signalling
Lorenzo Galluzzi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Structural Basis of TLR5-Flagellin Recognition and Signaling
Sung-il Yoon et al.
SCIENCE (2012)
Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells
Laura P. Schneider et al.
VACCINE (2012)
Sound efficacy of prophylactic HPV vaccination Basics and implications
Matti Lehtinen et al.
ONCOIMMUNOLOGY (2012)
Trial Watch Experimental Toll-like receptor agonists for cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Trial watch FDA-approved Toll-like receptor agonists for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Accessory molecules for Toll-like receptors and their function
Clarissa C. Lee et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs
Harm C. Arentsen et al.
BJU INTERNATIONAL (2011)
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
Taro Kawai et al.
IMMUNITY (2011)
Targeting Epidermal Growth Factor Receptor to Optimize Chemoradiotherapy in Locally Advanced Head and Neck Cancer: Has Biology Been Taken Into Account? Reply
Ezra E. W. Cohen
JOURNAL OF CLINICAL ONCOLOGY (2011)
Preliminary results of an ongoing phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line induction therapy (IMPACT Study).
M. Tschaika et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials
Jitka Fucikova et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Targeting Toll-like receptors: emerging therapeutics?
Elizabeth J. Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
Alexandre Carpentier et al.
NEURO-ONCOLOGY (2010)
A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
Sylvie Bertholet et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
A clinical grade poly I:C-analogue (Ampligen (R)) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro
H. Navabi et al.
VACCINE (2009)
Toll-like receptors and cancer
Seth Rakoff-Nahoum et al.
NATURE REVIEWS CANCER (2009)
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models
Lyudmila G. Burdelya et al.
SCIENCE (2008)
Synthetic agonists of Toll-like receptors 7, 8 and 9
S. Agrawal et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Toll-like receptors in tumor immunotherapy
Chrystal M. Paulos et al.
CLINICAL CANCER RESEARCH (2007)
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib
Thibault de la Motte Rouge et al.
CANCER RESEARCH (2007)
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier et al.
NEURO-ONCOLOGY (2006)
Successful combination of local CpG-ODN and radiotherapy in malignant glioma
YX Meng et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
The evolution of vertebrate Toll-like receptors
JC Roach et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists
ER Kandimalla et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
IRF-7 is the master regulator of type-I interferon-dependent immune responses
K Honda et al.
NATURE (2005)
Identification of Lps2 as a key transducer of MyD88-independent TIR signalling
K Hoebe et al.
NATURE (2003)
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway
M Yamamoto et al.
SCIENCE (2003)
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5
F Hayashi et al.
NATURE (2001)
FLS2:: An LRR receptor-like kinase involved in the perception of the bacterial elicitor flagellin in Arabidopsis
L Gómez-Gómez et al.
MOLECULAR CELL (2000)
Share Paper
